Charles Darwin University

CDU eSpace
Institutional Repository

 
CDU Staff and Student only
 

Reduced dose human papillomavirus vaccination: An update of the current state-of-the-art

Toh, Zheng Quan, Licciardi, Paul V., Fong, James, Garland, Suzanne M., Tabrizi, Sepehr N., Russell, Fiona M. and Mulholland, Edward K. (2015). Reduced dose human papillomavirus vaccination: An update of the current state-of-the-art. Vaccine,33(39):5042-5050.

Document type: Journal Article
Citation counts: Altmetric Score Altmetric Score is 5
Google Scholar Search Google Scholar

IRMA ID 81144320xPUB143
Title Reduced dose human papillomavirus vaccination: An update of the current state-of-the-art
Author Toh, Zheng Quan
Licciardi, Paul V.
Fong, James
Garland, Suzanne M.
Tabrizi, Sepehr N.
Russell, Fiona M.
Mulholland, Edward K.
Journal Name Vaccine
Publication Date 2015
Volume Number 33
Issue Number 39
ISSN 0264-410X   (check CDU catalogue  open catalogue search in new window)
Scopus ID 2-s2.0-84941742503
Start Page 5042
End Page 5050
Total Pages 9
Place of Publication United Kingdom
Publisher Elsevier Ltd
HERDC Category C1 - Journal Article (DIISR)
Abstract Human papillomavirus (HPV) infection is the primary cause of genital warts, some oropharyngeal cancers and anogenital cancers, including cervical, vagina, vulvar, anal and penile cancers. Primary prevention of cervical cancer requires the prevention of high-risk HPV infections, particularly HPV genotypes 16 and 18. Both Gardasil® and Cervarix® vaccines when administered by a three-dose schedule have been demonstrated to be effective against cervical, vulva, and vaginal cancer precursors from vaccine genotypes in phase III clinical trials, and post-marketing studies; Gardasil® vaccine also offers additional protection against anal cancer precursors. However, high costs of HPV vaccines and the logistics of delivering a three-dose schedule over 6 months are challenging in countries with limited resources. Several studies have demonstrated non-inferiority in antibody response between adolescents (9–15 years old) who received two doses (6 months apart) and women (>15 years old) who received the standard three-dose schedule. These studies provided evidence for the World Health Organization and European Medical Association to revise its recommendation to give two instead of three doses of HPV vaccine to adolescents below 15 years of age, provided the 2nd dose is given 6 months apart. Although reduced dose schedules can alleviate costs and logistics associated with HPV vaccination, especially in resource-poor countries, there are still gaps in this area of research, particularly regarding long-term protection. This review discusses the findings on antibody response and clinical outcomes in studies evaluating reduced dose HPV schedules, and highlights the important considerations of its implementation. In addition, other important immunological biomarkers that may be associated with long-term protection are highlighted and discussed.
Keywords Human papillomavirus
Cervical cancer
HPV vaccines
Reduced dose schedules
Antibody response
Long term protection
DOI http://dx.doi.org/10.1016/j.vaccine.2015.07.102   (check subscription with CDU E-Gateway service for CDU Staff and Students  check subscription with CDU E-Gateway in new window)
 
Versions
Version Filter Type
Access Statistics: 6 Abstract Views  -  Detailed Statistics
Created: Tue, 26 Jul 2016, 12:35:35 CST